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Abstract
Background: Although the systemic administration of cannabinoids produces antinociception, their
chronic use leads to analgesic tolerance as well as cross-tolerance to morphine. These effects are mediated
by cannabinoids binding to peripheral, spinal and supraspinal CB1 and CB2 receptors, making it difficult to
determine the relevance of each receptor type to these phenomena. However, in the brain, the CB1
receptors (CB1Rs) are expressed at high levels in neurons, whereas the expression of CB2Rs is marginal.
Thus, CB1Rs mediate the effects of smoked cannabis and are also implicated in emotional behaviors. We
have analyzed the production of supraspinal analgesia and the development of tolerance at CB1Rs by the
direct injection of a series of cannabinoids into the brain. The influence of the activation of CB1Rs on
supraspinal analgesia evoked by morphine was also evaluated.
Results: Intracerebroventricular (icv) administration of cannabinoid receptor agonists, WIN55,212-2,
ACEA or methanandamide, generated a dose-dependent analgesia. Notably, a single administration of
these compounds brought about profound analgesic tolerance that lasted for more than 14 days. This
decrease in the effect of cannabinoid receptor agonists was not mediated by depletion of CB1Rs or the
loss of regulated G proteins, but, nevertheless, it was accompanied by reduced morphine analgesia. On
the other hand, acute morphine administration produced tolerance that lasted only 3 days and did not
affect the CB1R. We found that both neural mu-opioid receptors (MORs) and CB1Rs interact with the
HINT1-RGSZ module, thereby regulating pertussis toxin-insensitive Gz proteins. In mice with reduced
levels of these Gz proteins, the CB1R agonists produced no such desensitization or morphine cross-
tolerance. On the other hand, experimental enhancement of Gz signaling enabled an acute icv
administration of morphine to produce a long-lasting tolerance at MORs that persisted for more than 2
weeks, and it also impaired the analgesic effects of cannabinoids.
Conclusion: In the brain, cannabinoids can produce analgesic tolerance that is not associated with the
loss of surface CB1Rs or their uncoupling from regulated transduction. Neural specific Gz proteins are
essential mediators of the analgesic effects of supraspinal CB1R agonists and morphine. These Gz proteins
are also responsible for the long-term analgesic tolerance produced by single doses of these agonists, as
well as for the cross-tolerance between CB1Rs and MORs.
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The cannabinoid receptors belong to the G protein-cou-
pled receptor (GPCR) superfamily and include at least
two receptor types: CB1 and CB2 [1-3]. The systemic
administration of endocannabinoids, such as anandam-
ide, the synthetic agonist [(R)-(+)-[2,3-dihydro-5-methyl-
3-(4-morpholinylmethyl) pyrrolo [1,2,3-de]-1,4-benzox-
azin-6-yl]-1-naphthalenylmethanone] (WIN55,212-2) or
the naturally occurring compound Δ9-tetrahydrocannabi-
nol (THC), produces analgesia in rodent pain models.
Unfortunately, long-term administration of agonists leads
to a progressive decrease in the cannabinoid-mediated
effects, a process referred to as analgesic tolerance [4,5],
which persists for as long as 14 days [6]. The tolerance that
follows repeated systemic administration of cannabinoids
is caused by down-regulation and/or uncoupling of the
receptors from the G proteins [1]. Most cannabinoids
induce rapid internalization of their receptors via clathrin-
coated pits [7], and long-term treatment leads to a signif-
icant down-regulation of CB1 receptors (CB1Rs). Indeed,
an important fraction of the internalized receptors is
transported to the lysosomal compartment for degrada-
tion, and the interaction between CB1Rs and G protein-
associated sorting protein 1 (GASP1) plays an essential
role in this process [8,9].
In the brain, CB1R is expressed at high levels in neural
cells, whereas CB2R exists only at low levels [10]. Thus,
CB1R appears to mediate the supraspinal effects of can-
nabinoid agonists. CB1R is found in the cerebral cortex,
amygdala, hippocampus, basal ganglia, cerebellum, and
brain areas involved in descending pain modulation, such
as the periaqueductal gray matter (PAG), rostral ventro-
medial medulla (RVM), and the spinal cord [10]. This dis-
tribution is consistent with the effects of cannabinoids on
emotional responses, cognition, memory, movement,
and nociception [11-13]. At the molecular level, CB1R
couples to pertussis toxin (PTX)-sensitive Gi/o proteins
[14,15] and to certain pertussis toxin-insensitive G pro-
teins, probably Gq/11 and Gz [16,17]. This receptor regu-
lates the expression of immediate early genes and various
cellular effectors, such as adenylyl cyclase, ion channels,
mitogen-activated protein kinase, and focal adhesion
kinase [1,3,18].
Interestingly, cannabinoids may be useful in controlling
pathological pain that is resistant to conventional opioid
therapies [19,20]. Although cannabinoids act independ-
ently of opioids to produce analgesia in rodents, similar
brainstem circuitry seems to be involved [21]. Brain areas
such as the caudate putamen, dorsal hippocampus, and
substantia nigra are rich in both cannabinoid and opioid
receptors, and the co-localization of both types of recep-
tors has been described [10,22]. Loss of functional recep-
tors leads to desensitization in both systems. Chronic
treatment induces analgesic cross-tolerance between opi-
oids and cannabinoids. This cross-tolerance, however,
occurs without any change in the receptors of the other
system [23,24]. This observation suggests that interactions
can take place at the signal transduction/effector level. In
nervous tissue, desensitization in response to single doses
of opioids, such as morphine, occurs without the loss of
surface receptors. However, in response to subsequent
doses of morphine, the MOR becomes phosphorylated
and undergoes internalization/recycling [25]. In contrast
to what happens with the CB1R, few internalized MORs
are destroyed in the lysosomal fraction [26,27]. Rather,
most of the internalized MORs are re-inserted in the
membrane, and tolerance to opioids that induce robust
receptor internalization develops slowly [28,29].
A series of recent studies have increased our knowledge of
the molecular mechanisms implicated in neural MOR sig-
naling and desensitization. In nervous tissue, the C-termi-
nus of MOR interacts with a signaling module consisting
of histidine triad nucleotide binding protein 1 (HINT1)
that is associated with the Gz regulatory proteins RGS17
(RGSZ2) and RGS20 (RGSZ1). The RGSZ proteins are spe-
cific GTPase-activating proteins (GAPs) of receptor-acti-
vated Gαz-GTP subunits. Thus, this HINT1-RGSZ
signaling module is physically close to the MOR-regulated
Gz proteins and helps to deactivate the agonist-activated
Gαz-GTP subunits [30-32]. For opioids such as morphine,
which induce little MOR internalization, neural-specific
Gz proteins are essential to the desensitization of suprasp-
inal antinociception.
Given the relevance of brain CB1Rs as analgesics, in the
present study we sought to analyze supraspinal antinocic-
eption and its desensitization following icv administra-
tion of cannabinoid agonists. The results indicate that
CB1Rs, like MORs [32], interact with the HINT1-RGSZ
signaling module. Both receptors regulate Gz proteins to
produce supraspinal analgesia, and this G protein is
implicated in their desensitization and cross-desensitiza-
tion.
Results
Single-dose analgesic desensitization of brain CB1 
receptors: time required to recover the initial response
The CB1R agonists methanandamide, ACEA, and
WIN55,212-2 all produced dose-dependent antinocicep-
tion in the tail-flick test when injected icv into mice (Fig.
1, upper panel); this antinociception was antagonized by
the cannabinoid antagonist AM-251 (data not shown).
These effects showed rapid onset, typically within 5 to 10
min post-injection, and then declined slowly. Doses of 50
nmol methanandamide, 40 nmol ACEA, or 20 nmol
WIN55,212-2 produced comparable peak analgesic
effects, which were approximately 70% of the maximumPage 2 of 22
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an acute dose of these agonists caused a robust analgesic
desensitization, and a second administration of either
agonist 24 h after the priming dose produced almost no
detectable analgesia (Fig. 1, middle panel). Because inhib-
iting PKC reverses single-dose analgesic tolerance to opio-
ids such as morphine [see references in [33]], we tested the
effect of injecting 1 nmol of the PKC inhibitor Gö7874 icv
30 min before the second dose of the agonists. Contrary
to our expectations, this approach failed to rescue the
analgesic effect of the cannabinoid agonists.
We next studied the interval required to recover the initial
analgesic response. Mice received a desensitizing priming
dose of the agonists, and were then divided into sub-
groups. Each subgroup received a second test dose of the
agonist at different intervals after the priming dose. Nota-
bly, the CB1R desensitization caused by a single dose of
the cannabinoid agonist lasted for several days and the
recovery of the response took 2 or 3 weeks (Fig. 1, lower
panel). This result differs from that observed in acute tol-
erance to morphine, which lasts only 3 or 4 days [34]. In
this way, our results indicate that the CB1R agonists stud-
ied produce dose-dependent supraspinal analgesia, which
leads to significant and long-lasting desensitization of the
receptor. We then analyzed a series of mechanisms that
could be responsible for this CB1R tolerance.
Internalization of CB1Rs evoked in mouse brain by CB1R 
agonists
A plausible explanation for the observed long-lasting sin-
gle-dose desensitization of CB1Rs is that the agonists
reduced the functional CB1Rs at the neural membrane.
Because most of the neuronal CB1Rs are associated with
synaptic terminals [35-37], our study was performed on
the membrane fraction enriched in synaptosomes. Then,
in order to directly evaluate the presence of the CB1Rs in
the synaptosomal membrane, we developed two antibod-
ies that recognize extracellular domains on the CB1 recep-
tor: one is directed against a peptide sequence in the N
terminus (Nt) and the other against the first extracellular
loop (1EL). These antibodies were affinity-purified using
the corresponding antigenic peptide sequence, and their
ability to label the target proteins in neural cells was
assessed. With this aim, living cultured astrocytes were
incubated, in the absence of detergents, with the anti-
CB1R antibodies, Nt or 1EL, which had been covalently
attached to the fluorescent label, Alexa-488. Under condi-
tions of no detergent, Triton X-100 does not disrupt the
lipid bilayer and the IgGs do not penetrate into the living
cells. In this case, both antibodies labeled only surface
CB1Rs (Fig. 2A; Nt, A1 and A3; 1EL, A2). This labeling was
not observed when the living astrocytes had been pre-
treated with the cannabinoid agonist WIN55,212-2 (Fig.
2B). These observations indicate that both antibodies
label extracellular epitopes of the CB1R and that
WIN55,212-2 reduces its surface expression, probably by
inducing receptor internalization.
In order to detect the internalized CB1Rs, the living astro-
cytes were exposed to WIN55,212-2 and then incubated
with a fixative solution that modifies extracellular
sequences of surface proteins, such as the CB1Rs. How-
ever, if the integrity of the cell membrane is preserved, the
fixative does not reach and alter the sequences of the
cytosolic proteins. The anti-CB1R antibodies were then
added in a medium containing 0.1% Triton X-100 to dis-
organize the lipid membrane. In doing so, the antibodies
failed to bind the corresponding epitopes on the surface
CB1Rs (compare Fig. 2A and 2C), but reached the intact
epitopes on the internalized CB1Rs (Nt, D1 and E1; 1EL,
D2 and E2). Therefore, WIN55,212-2 at concentrations of
0.1 μM and 1 μM, promoted the internalization of the
CB1Rs (Fig. 2C and 2D). These results indicate that the Nt
and 1EL antibodies bind to CB1Rs. Moreover, both anti-
bodies recognized the recombinant CB1R protein in
immunoblotting assays (Fig. 3A).
The supraspinal analgesic effects of icv-injected opioids
and cannabinoids occur mainly through their respective
binding to MORs and CB1Rs in the midbrain [10,12,38-
40]. These substances act on the PAG to RVM connection,
Long-term supraspinal analgesic tolerance produced by agonists of brain CB1RsFigur  1 (see previous page)
Long-term supraspinal analgesic tolerance produced by agonists of brain CB1Rs. Upper panel: Mice were injected 
icv with methanandamide, ACEA or WIN55,212-2 at the doses indicated, and analgesia was evaluated at various intervals post-
injection using the "tail-flick" test with a thermal stimulus of a 52°C water bath. Middle panel: A priming dose of methanandam-
ide (50 nmol), ACEA (40 nmol), WIN55,212-2 (20 nmol), or saline was administered icv to mice (n = 10 per group). After 24 
h, single-dose tolerance was examined by administering a test dose of each agonist (same dose as the priming dose) to mice 
that had received either saline (open bars) or the priming doses (grey bars). In another set of assays, mice that had received the 
priming doses of the corresponding agonists were injected icv 24 h later with the PKC kinase inhibitor Gö7874 (1 nmol), and 
30 min later with test doses of the cannabinoid agonists (dark grey bars) (n = 10 per group). The "tail-flick" test was conducted 
10 min after agonist administration. Bars represent mean ± SEM. *Significantly different from the saline control group (P < 
0.05). Lower panel: Recovery from the acute analgesic tolerance produced by the CB1R agonists. The "tail-flick" test was con-
ducted 10 min after injection of the test dose. Data are expressed as mean ± SEM from groups of 8 mice.Page 4 of 22
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WIN55,212-2 promotes internalization of CB1Rs in cultured astrocytesFigure 
WIN55,212-2 promotes internalization of CB1Rs in cultured astrocytes. Labeling of surface CB1Rs in living astrocytes: 
astrocytes were incubated with WIN55,212-2 for 1 h, then CB1R antibodies (1:500) labeled with Alexa-488 were added to the 
cultures for 30 min. The antibodies were washed out and the tissue was fixed. The CB1R was labeled by antibodies targeting 
the first external loop (1L) or the N-terminus (Nt). Anti-CB1R Nt was used in A1, B1, A3, and B3; anti-CB1R 1EL was used in 
A2 and B2. Green = CB1R, blue = DAPI; magnification = 60×. Labeling of internalized CB1Rs in fixed astrocytes: astrocytes were 
first incubated with WIN55,212-2 for 1 h. Afterwards they were fixed and incubated with a solution containing 0.1% Triton 
X100. The CB1R antisera were added in this solution and incubated for 2 h. Anti-CB1R Nt was used in C1, D1, and E1; anti-
CB1R 1EL was used in C2, D2, and E2. Details in Methods and Results.
Molecular Pain 2009, 5:11 http://www.molecularpain.com/content/5/1/11Figure 3 (see legend on next page)Page 6 of 22
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project down to the substantia gelatinosa in the dorsal
horn of the spinal cord and reduce the intensity of the
ascending nociceptive signals [41,42]. Therefore, to com-
pare the analgesic effects with molecular events, we exam-
ined the discrete neural structure, the PAG. The neural
CB1R has been described as heavily glycosylated [43].
Consequently, our anti-CB1R antibodies revealed a step-
ladder pattern, reflecting differently glycosylated popula-
tions. The covalently bound sugar branches prevent CB1R
from adopting the globular shape that is expected for pro-
teins subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). Thus, sugars reduce the
mobility of this protein through the pores of the gel and
produce the observed bands (ladder steps), depending on
the kind of sugar or the extent of the glycosylation [44].
This stepladder pattern was also observed when the recep-
tor was immunoprecipitated from the synaptosomal glyc-
osylated protein fraction (obtained by WGL affinity
chromatography) and analyzed using the other CB1R
antibody (Fig. 3A). In neurons, glycosylation of GPCRs is
very common and produces similar patterns after SDS-
PAGE (e.g., μ- and δ-opioid receptors) [[45] and refer-
ences therein].
For the sake of simplicity, we studied the agonist-induced
internalization of brain CB1Rs by focusing on the 55- to
60-kDa band. In these assays, the cannabinoid agonists
were used at acute doses that produced a long-lasting
analgesic tolerance. Early after icv ACEA or WIN55,212-2
administration and during their analgesic time-courses,
the level of cytosolic CB1Rs increased and the level of sur-
face CB1Rs decreased. This trend gradually changed after
an additional 48 h, such that the presence of this receptor
in the cytosol and at the cell surface had returned to the
levels observed in the absence of agonist (Fig. 3B and 3C).
In contrast, methanandamide induced a low to moderate
internalization of the CB1R (Fig. 3B). However, over sev-
eral days, the mice remained refractory to the analgesic
effects of additional doses of all these agonists.
A significant fraction of the internalized CB1Rs is shuttled
into lysosomes, where the receptors are degraded. There-
fore, the recovery of the surface CB1Rs observed after a
single dose of WIN55,212-2 indicates that CB1R turnover
takes about 28 h. In the absence of an exogenous agonist,
some of the cytosolic CB1R staining is not associated with
lysosomes and may indicate synthesis (Fig. 3C). In con-
trast, MOR, which has a turnover rate of 10 to 14 days, is
barely detectable in the cytosol in the absence of agonist
treatment [25]. After WIN55,212-2 challenge, CB1Rs were
internalized and their levels in early endosomes and lyso-
somes increased. These findings indicate that the CB1R is
being lysosomally degraded [9]. Based on the antibody
staining pattern, it appears that the transition between
early endosomes and lysosomes depends on the level of
CB1R glycosylation. The 55- to 60-kDa band remained in
the fraction containing early and recycling endosomes
longer than did the bands representing more slowly
migrating proteins, which rapidly associated with lyso-
somes (Fig. 3C). This also seems to be the case for the opi-
oid receptors: the heavily glycosylated forms had the
fastest turnover [46].
Methanandamide induced minimal internalization of
CB1Rs in the brain, but it did promote analgesic desensi-
tization. Moreover, surface synaptosomal CB1Rs depleted
by WIN55,212-2 and ACEA recovered long before the
analgesic response was restored. These observations indi-
cate that the acute analgesic tolerance produced by can-
nabinoid agonists given by the icv route is not due to the
loss of surface receptors.
Agonists of CB1Rs do not promote stable transfer of G 
proteins to RGS proteins
Receptor desensitization can be achieved without affect-
ing the levels of surface receptors. This has been observed
Agonist-induced internalization of brain CB1RsFigure 3 (see previous page)
Agonist-induced internalization of brain CB1Rs. A. The recombinant CB1 receptor (rCB1R) was labeled by both Nt and 
1EL antibodies. The CB1R in solubilized PAG synaptosomal membranes was precipitated with 1EL or Nt antibodies and then 
immunodetected using the other antibody, yielding a ladder pattern. This banding of CB1Rs was also observed in the purified 
glycosylated fraction of PAG membranes, indicating the presence of multiple glycosylated species. B. Cannabinoid agonists used 
at doses that desensitize analgesia caused the internalization of surface CB1Rs (P2) into the cytosol (S3). ACEA and 
WIN55,212-2 caused internalization, but methanandamide caused almost none. C. Upper panel: Presence of CB1Rs in the 
cytosolic fraction of brain tissue from mice that did not receive WIN55,212-2. The mice were killed and the PAG S3 fraction 
was subjected to subcellular fractionation in order to determine the presence of CB1Rs. Lower panel: Mice were injected icv 
with WIN55,212-2, then sacrificed 30 min later, and the PAG S3 cytosolic fraction was analyzed for the presence and distribu-
tion of internalized CB1Rs. Subcellular markers: Rab5 (BD 610281), EEA1 (early endosome antigen I; BD 610456), Rab4 (BD 
610888), Rab11 (BD 610656), Lamp-1 (lysosomal-associated membrane protein I; BD 61043). Right panel: The PAG cytosolic 
fraction was analyzed at various time intervals following administration of WIN55,212-2 in order to test for the presence of 
the CB1R.Page 7 of 22
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with no loss of surface MORs [25]. In the brain, most cases
of tolerance to morphine occur as a result of depletion of
the MOR-regulated G proteins, which are transferred to
RGS proteins belonging to the R7 and Rz subfamilies
[25,47,48]. In the mouse brain, the CB1R is associated
with different classes of G proteins. In the PAG, this recep-
tor co-precipitates with PTX-sensitive Gi and Go as well as
with PTX-insensitive Gq/11 and Gz (Fig. 4A).
WIN55,212-2 (20 nmol), which induces the internaliza-
tion of PAG CB1Rs, also promoted some transfer of Gαi
and Gαz subunits from CB1Rs toward RGSZ2 proteins.
However, this association was only transitory, and when
the CB1Rs gradually returned to the membrane, they reas-
sociated with the G proteins (Fig. 4B, C). This is not the
case for morphine, however, which promotes a long-term
transfer of Gi/z proteins toward RGSZ2 proteins and thus
a persistent decrease in the signaling capacity of MORs.
Interestingly, the opioid agonist [D-Ala2, N-Me-Phe4, Gly-
ol5]-encephalin (DAMGO), which stimulates robust
internalization of MORs, also promotes temporary associ-
ation of G proteins with RGSZ2 [25]. However, DAMGO
produces low levels of analgesic tolerance, whereas
WIN55,212-12, ACEA, and methanandamide induce a
significant and long-lasting tolerance. These observations
indicate that cannabinoid tolerance is not mediated by
reductions in CB1R-regulated transduction.
Influence of G proteins and RGS proteins in the 
desensitizing capacity of cannabinoids
We next explored whether cannabinoid desensitization is
caused by post-receptor events triggered by certain G pro-
teins and/or RGS proteins. To accomplish this, we used
antisense oligodeoxynucleotides (ODNs) targeting
mRNAs encoding specific Gα subunits and RGS proteins
in order to reduce the expression of these proteins. The
ODNs used have all been extensively characterized as
effective and selective in reducing expression of the
murine target protein and are referred to in the corre-
sponding studies: Gαz subunit [49,50]; Gαi2 subunit
[49,50]; Gαq/Gα11 [51]; RGS9-2 [48,52]; RGSZ2 [47];
PKCI/HINT1 [32].
The supraspinal analgesia evoked by CB1R agonists was
only partially sensitive to the effect of PTX [53]. This result
suggests the participation of both PTX-sensitive and PTX-
insensitive G proteins in supraspinal analgesia mediated
by CB1Rs. In our study, the analgesia produced by
WIN55,212-2 and methanandamide was more resistant
to the blocking effect of PTX than that of ACEA or THC
(Fig. 5A). Consistent with this observation, knockdown of
the PTX-sensitive Gαi2 proteins produced little change in
the activity of WIN55,212-2. Of the PTX-resistant G pro-
teins, knockdown of Gαz, but not Gαq, significantly
reduced the analgesic effects of WIN55,212-2 (Fig. 5B).
Besides, the supraspinal antinociception evoked by meth-
anandamide decreased when expression of Gαz was
reduced. This reduction was only moderated for THC and
ACEA (Fig. 5C). For all of the agonists studied, the desen-
sitization that followed was not significantly altered by
treating the mice with PTX (shown for WIN55,212-2, Fig.
5A). Notably, these Gαz knockdown mice did not
develop acute tolerance to the analgesic effects of cannab-
inoids when evaluated 24 h (Fig. 5B middle panel), 48 h
and 72 h later (not shown). The antinociceptive activity of
morphine is partially sensitive to PTX, and Gαi2 subunits
play a role (Fig. 5D) [50,54,55]. The morphine analgesic
effect is independent of Gαq subunits but strongly
decreases after Gαz knockdown [50,54,56].
The RGS9 protein is a negative regulator of morphine
activity and, in its absence, morphine has an increased
analgesic effect and induces less tolerance [52,57]. Never-
theless, the absence of RGS9 did not affect the activity of
WIN55,212-2 or its capacity to produce CB1R desensitiza-
tion. On the other hand, reduced RGSZ2 expression
caused increased Gz signaling and rapid desensitization of
MORs [47], which lasted for more than 2 weeks (Fig. 5E).
This pattern is consistent with CB1R desensitization pro-
duced by the acute doses of icv cannabinoid agonists (see
Fig. 1, lower panel). Therefore, the CB1R agonists appear
to produce long-lasting acute analgesic desensitization by
activating a signaling pathway in which Gz proteins play
an essential role.
Cross-tolerance between CB1Rs and MORs
WIN55,212-2 desensitized its own analgesic response
and, as expected for agonists sharing the receptor, it was
also desensitized by other CB1R agonists, such as meth-
anandamide, ACEA, and THC. This cross-desensitization
produced by acute doses of cannabinoid agonists was not
observed after reducing the expression of Gαz subunits
(Fig. 6, upper panel). We explored whether the interaction
between CB1R agonists and morphine was mediated by
the activation of Gz proteins. WIN55,212-2 diminished
the analgesic response of morphine, and this reduction
was observed even after 5 days of icv cannabinoid injec-
tion. Notably, in Gαz knockdown mice, WIN55,212-2
produced no cross-tolerance to morphine analgesia. How-
ever, the connection between CB1R and MOR persisted
when the expression of Gαi2 was reduced (Fig. 6, middle
panel). Thus, Gz plays a key role in impairing the activity
of the CB1R agonist, WIN55,212-2, on morphine-pro-
moted analgesia. An interesting result is that WIN55,212-
2 failed to reduce the response to DAMGO (Fig. 6, lower
panel).
Acute administration of opioids at their analgesic ED80,
regardless of whether their ability to activate Gz proteins
was strong (morphine), moderate (DAMGO), or lowPage 8 of 22
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Molecular Pain 2009, 5:11 http://www.molecularpain.com/content/5/1/11(DADLE) [51,58], produced no reductions in the analge-
sic effects of WIN55,212-2. Clonidine, an agonist of α2
adrenoreceptors that activates Gz proteins [59], also failed
to alter the activity of the CB1R agonist (Fig. 7, upper
panel). These results indicate that acute desensitization
operates only in the direction from the CB1R toward the
MOR. It may be that MORs as well as α2A receptors effi-
ciently regulate Gz-mediated signaling, thereby promot-
ing little desensitization of Gz target effectors. In fact,
MOR tolerance produced by an acute dose of morphine
lasted for only 3 or 4 days (e.g., Fig. 5D), whereas that of
CB1R agonists persisted for more than 14 days. Consistent
with this idea, deregulation of receptor-activated Gαz-
GTP subunits through reduction in the expression of its
GAP, the RGSZ2 protein, leads to profound desensitiza-
tion of morphine analgesia [47,54]. Under these circum-
stances, the tolerance evoked by a single dose of morphine
lasted as long as that observed following acute icv doses of
the CB1R agonists (see Fig. 5E).
To add consistency to these results, we considered the pos-
sibility that morphine diminishes CB1R activity after
deregulation of Gz proteins. However, after knockdown
of RGSZ2 proteins, the analgesic effects of both morphine
and WIN55,212-2 were greatly reduced; thus, no interac-
tion could be reliably studied. To circumvent this diffi-
culty, we considered an alternative approach to deregulate
the receptor-activated Gz proteins. The HINT1-RGSZ sign-
aling module on the C-terminus of MORs helps control
the MOR-induced activation of Gz proteins [30-32]. The
absence of HINT1 dissociates RGSZ proteins from MORs
and reduces the deactivation of the morphine-activated
Gαz-GTP subunits. Consistent with this, morphine dis-
plays a higher analgesic potency in HINT1 knockout/
knockdown mice [31,32]; we also observed an increased
analgesic effect of WIN55,212-2 in these mice (Fig. 7,
lower panel). These increases in morphine and
WIN55,212-2 analgesic effects were followed by a greater
tolerance to their respective analgesic effects. However,
this analgesic tolerance was of a lesser magnitude than
that observed when RGSZ2 was depleted [31,32] and per-
mitted the study of the influence of morphine on
WIN55,212-2 antinociceptive effects. Most relevant, in
those HINT1 knockdown mice, morphine effectively
reduced the analgesia evoked by WIN55,212-2 (Fig. 7,
lower panel).
The neural CB1R interacts with the HINT1-RGSZ module
The results of this study so far indicate that brain CB1R
regulates neural-specific Gz proteins. We next analyzed
the possible linkage of the CB1R to the HINT1-RGSZ
module originally described for the MOR [30], which also
couples to Gz proteins [49]. We found that HINT1 co-pre-
cipitates with both MORs and CB1Rs. Moreover, both
receptors co-precipitated RGSZ1 and RGSZ2 proteins.
However, the δ-opioid receptor, which does not regulate
Gz proteins in brain tissue [49], precipitated almost no
RGSZ proteins (Fig. 8, upper panel). The pattern of RGSZ
bands detected resembled a stepladder due to the hetero-
geneity in glycosylation and sumoylation [60].
As described for the HINT1-RGSZ module when bound to
the MOR C-terminus [32], the CB1R also increased its
association with the ser/thr kinase, PKCγ, in the presence
of free zinc ions (Fig. 8, middle panel). Thus, administra-
tion of morphine promotes increases in the association of
PKCγ with the MOR-HINT1-RGSZ complex, probably in
order to phosphorylate and uncouple the receptor from
downstream G proteins. Likewise, WIN55,212-2 injected
icv into the mice also promoted an increase in the associ-
ation of CB1R-HINT1-RGSZ with this kinase. This
increased association of PKC was most often observed
when the association of G proteins with CB1R decreased
(compare Fig. 4B and lower panel of Fig. 8). Thus, the
recruited PKCγ plays a role in uncoupling the CB1R from
regulated transduction before it becomes internalized.
WIN55,212-2 promotes reversible transfer of CB1R-regulated G proteins toward RGSZ2 proteinsFigure 4 (see evious pag )
WIN55,212-2 promotes reversible transfer of CB1R-regulated G proteins toward RGSZ2 proteins. A. Gα subu-
nits co-precipitated with CB1Rs in PAG membranes. These proteins were assayed using antibodies to different Gα subunits. 
Gαz was studied using an antibody targeting the helical domain (1) and an antibody targeting the C-terminus (2). B. Groups of 
mice received a single icv injection of WIN55,212-2 (20 nmol) and were killed at the time points indicated. For each time point 
studied the PAG structures from 6 to 8 mice were pooled. The CB1R, RGSZ2, and associated proteins were then studied in 
PAG membranes. The immunosignals associated with these signals (average optical density of the pixels within the object area/
mm2; Quantity One Software, BioRad) were expressed relative to the levels observed for the control group (attributed an 
arbitrary value of 1). Each bar is the mean ± SEM of three assays performed on PAG samples obtained from independent 
groups of mice. *Significantly different from the PAG control group (P < 0.05). C. Stimulated [35S]GTPγS binding by 
WIN55,212-2 in PAG membranes from mice injected with a cannabinoid agonist. Membranes from mice treated with vehicle 
(control; closed symbols) or exposed to WIN55,212-2 (20 nmol/mouse; open symbols) were obtained 30 min and 48 h after 
icv injection and incubated in [35S]GTPγS (0.1 nM) and increasing concentrations of WIN55,212-2. *Significantly different from 
the PAG control group (P < 0.05).Page 10 of 22
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This study has shown that acute icv administration of can-
nabinoids promotes a long-lasting and robust desensitiza-
tion of supraspinal CB1Rs, which could be mediated by
post-receptor events. The analgesic tolerance that is
observed after ip or sc administration of these substances
usually requires repeated injections and affects both CB1
and CB2 receptors at spinal and supraspinal levels
[10,61]. This long-term cannabinoid administration pro-
duces CB1R desensitization and down-regulation [6].
Specifically, supraspinal CB1R expression diminishes, as
does the ability of systemic cannabinoids to induce
hypoactivity, hypothermia, and antinociception [5,8,9].
Up to 2 weeks are required to recover the initial levels of
CB1Rs in the synaptosomal membrane as well as the anal-
gesic response to cannabinoids [5,6,9,62]. Therefore, the
analgesic tolerance that follows the repeated systemic
administration of cannabinoids can be explained in terms
of the loss of surface CB receptors.
Brain CB1Rs, however, desensitize in response to acute
doses of agonists; this cannot be explained merely in
terms of a permanent loss of receptors. The effect of a sin-
gle icv-injection of ACEA or WIN55,212-2 on surface
CB1Rs is certainly brief. During the analgesic time-course
of these agonists, the CB1Rs decreased in the PAG mem-
brane by 60–70%. Most of the internalized CB1Rs bind to
GASP1 and are then degraded in the lysosomal compart-
ment [8,9]. After the analgesic effects of single doses of the
cannabinoids cease, the CB1Rs are gradually restored to
the surface, probably by both the recycling of a portion of
the internalized receptors and the insertion of newly syn-
thesized receptors. As a result, 24 h or 48 h later, the pres-
ence of CB1Rs in the membrane is comparable to that
seen before the agonist challenge. During this time, the
restored CB1Rs become coupled to G proteins, but the
analgesic response takes a significantly longer time to be
restored: about 14 days. Most relevant, this tolerance is
also promoted by cannabinoids such as methanandam-
ide, which cause almost no loss of surface CB1Rs. Thus, it
is likely that the analgesic desensitization promoted after
several days of systemic treatment with cannabinoids pri-
marily affects receptors at the spinal and peripheral levels,
and the associated downregulation of the supraspinal
CB1Rs, about 30–50% [5,62], may be secondary to these
effects.
There is compelling evidence that the CB1R couples to
and regulates both PTX-sensitive Gi/o proteins and PTX-
insensitive Gq/11 and Gz proteins. Thus, the endocan-
nabinoid, 2-arachidonoylglycerol, protects neurons by
limiting cyclooxygenase-2 expression, an effect mediated
by PTX-sensitive G proteins [15]. WIN55,212-2 shows a
more complex pattern of receptor activation. Whereas this
agonist affects acetylcholine release in the hippocampus
through a PTX-sensitive mechanism [63], in cultured hip-
pocampal neurons it promotes increases in intracellular
calcium via CB1Rs and the PTX-insensitive Gq protein.
Interestingly, the latter effect is not reproduced by other
cannabinoids, such as THC, CP55,940, 2-arachidonoylg-
lycerol, or methanandamide [16]. These results indicate
that after binding the CB1R, cannabinoids may determine
the class(es) of G proteins to be activated. Indeed, in a cell
line derived from human trabecular meshwork, which is
an ocular tissue, WIN55,212-2 was shown to increase
intracellular calcium via CB1R and Gq/11 proteins and to
Neural-specific Gz proteins mediate supraspinal analgesic desensitization produced by CB1R and MOR agonistsFig re 5 (see previous page)
Neural-specific Gz proteins mediate supraspinal analgesic desensitization produced by CB1R and MOR ago-
nists. A. Effect of Pertussis toxin (PTX) on the supraspinal analgesia produced by cannabinoid agonists. PTX injected icv to 
mice (0.5 μg) was given 6 days before the agonist [55]. Left panel: Open bars indicate controls; gray bars indicate mice treated 
with PTX. Right panel: The influence of PTX on the analgesic time-course of 20 nmol WIN55-212-2 and on its single-dose tol-
erance was studied. Either saline (S) or the priming dose of the agonist (W) was administered icv to mice. After 24 h, all groups 
received an icv test injection of WIN55,212-2 (S+W; W+W), and the analgesic effects were evaluated 10 min later. Values are 
mean ± SEM for groups of 8–10 mice. *Significantly different from the control group injected with saline instead of the priming 
dose of WIN55,212-2 and also receiving the test dose of agonist (S+W) (P < 0.05). B. Time-course for the supraspinal analgesic 
effects of WIN55,212-2 was evaluated in mice that had been subjected to different icv treatments. Reduction in the levels of 
certain proteins was attained using oligodeoxynucleotides directed against Gαq [51], Gαi2 [49,50], Gαz [49,50], RGS9 [48,52], 
and RGSZ2 [47]. ODN-RD stands for the control mismatched ODN. Values are mean ± SEM from groups of eight mice. *Sig-
nificantly different from the control group injected with either saline or the corresponding control ODN (P < 0.05). The effect 
of these treatments on the single-dose tolerance produced by 20 nmol WIN55,212-2 was studied as described above. C. The 
analgesic effects of WIN55,212-2, THC, ACEA and methanandamide was studied in mice with impaired expression of Gαz sub-
units. D. A parallel study was carried out with morphine in mice subjected to the indicated treatments. Data corresponding to 
the peak effect of morphine at 30 min are shown. Findings from RGS9 knockdown mice are also shown at 60 min. Values are 
mean ± SEM from groups of eight mice. *Significantly different from the control group injected with saline (for PTX) or the 
corresponding control ODN (P < 0.05). E. Recovery from the acute analgesic tolerance produced by morphine in control mice 
and mice with reduced expression of RGSZ2 protein. For details see Fig. 1, lower panel.Page 12 of 22
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proteins. In this system, CP55,940 and methanandamide
produced the same effects, but they acted via PTX-sensi-
tive Gi/o proteins [17]. Therefore, the CB1R, like the
MOR, couples to a series of PTX-sensitive and -insensitive
G proteins, and the agonists determine the pattern of G
protein activation [56,58,64].
Brain CB1Rs mediate the production of analgesia via PTX-
sensitive and PTX-insensitive G proteins [[53] and present
study]. The spinal-mediated analgesic action of cannabi-
noids is mostly mediated via Gi/o proteins. Intrathecal
administration of PTX also abolishes the analgesia evoked
by icv cannabinoids, indicating that the descending path-
ways triggered by these substances act at the spinal level
through receptors coupled to Gi/o proteins [65]. Signaling
via the neural-specific PTX-insensitive Gz protein appears
to occur more at the supraspinal level [55,66]. In fact,
supraspinal analgesia mediated by MORs has an impor-
tant Gz component [56]; at the spinal level, in contrast,
PTX abolishes most MOR-mediated analgesia [66,67].
Consistent with this observation, the levels of expression
of specific regulators of activated Gαz subunits, GAPs,
RGSZ1, and RGSZ2, are lower in the spinal cord than in
the midbrain [47,54].
Activation of Gz proteins mediates long-lasting analgesic
desensitization of supraspinal CB1Rs. Cannabinoid ago-
nists, such as methanandamide, which apparently do not
activate Gq/11 proteins [16,17], produced desensitization
of CB1Rs via activation of Gz proteins. Therefore, it seems
that agonists that trigger activation of Gi/o proteins via
CB1Rs also activate the PTX-insensitive Gz protein. The
unique biochemical and regulatory properties of Gαz sub-
units account for their strong ability to desensitize GPCR
signaling events. The Gz transducer protein, like Gi/o pro-
teins, regulates adenylyl cyclase activity and the gating of
certain K+ channels. Gαz, however, is predominantly con-
fined to neuronal cells. The rate of Gαz-GTP hydrolysis is
as much as 200-fold slower than that of Gαs-GTP and
Gαi-GTP. Therefore, Gz may be resistant to inactivation
after receptor activation unless external factors accelerate
the rate of Gαz-GTP hydrolysis, much the same way that
the GAPs do for many Ras-like proteins. Therefore, inade-
quate control of Gαz signaling may easily lead to over-reg-
ulation of target effectors and subsequent desensitization
[47]. Thus, deactivation requires the assistance of specific
GAPs to augment the rate of hydrolysis and thus release
effector(s) from continuous regulation.
The RGS-Rz subfamily bears the primary responsibility for
regulating Gz, and the C-terminus of the MOR associates
with a signaling module consisting of HINT1-RGSZ,
which helps deactivate MOR-activated Gαz-GTP subunits
[30]. This study has shown that brain CB1Rs regulate Gz
proteins and associate with the HINT1-RGSZ signaling
module, which is involved in the zinc-mediated recruit-
ment of PKCγ [32]. Indeed, PKC has been implicated in
the desensitization of CB1Rs by phosphorylation of a ser-
ine residue (S317) in the third internal loop [68]. We have
observed the in vivo recruitment of PKCγ toward the
HINT1-RGSZ module at the C-terminus of CB1R during
the intervals when the receptor is uncoupled from regu-
lated transduction. However, the inhibition of this kinase
did not prevent the development of acute tolerance, sug-
gesting that other post-receptor mechanisms operate in
this process. Most relevant, deregulation of this module
brings about increased Gz signaling at the corresponding
effector(s) and the development of profound analgesic
desensitization of brain MORs [47,50,54] and CB1Rs
(present study). In contrast, depletion of Gz proteins
reduces the analgesic desensitization produced by icv
injection of various doses of morphine [50] and also abol-
ishes acute desensitization of brain CB1Rs and cross-toler-
ance with morphine. A single icv injection of morphine
produces desensitization that lasts for approximately 3
days; however, the cannabinoid agonists studied here
desensitized CB1Rs for more than 14 days. Because both
of these effects were mediated by the activation of Gz pro-
teins, this observation indicates that CB1R-activated Gz
Role of Gz proteins in the ability of WIN55,212-2 to reduce morphine analgesiaFigure 6 (see previous page)
Role of Gz proteins in the ability of WIN55,212-2 to reduce morphine analgesia. Upper panel: Cross-tolerance 
between CB1R agonists in wild type and Gαz knockdown mice. A priming dose of WIN55,212-2 (icv; 30 nmol) was adminis-
tered to the mice, and their response to WIN55,212-2, methanandamide, ACEA or THC was evaluated 24 h later. Values are 
mean ± SEM from groups of eight mice. *Significantly different from the control group injected with the vehicle instead of the 
priming dose of WIN55,212-2 and also receiving the test dose of this agonist (P < 0.05). Middle panel: WIN55,212-2 does not 
reduce morphine analgesia in mice showing reduced expression of Gαz subunits. The activity of WIN55,212-2 on morphine-
evoked antinociception was studied in mice showing reduced expression of either Gαi2 or Gαz subunits. *Significantly differ-
ent from the control group injected with the vehicle instead of the priming dose of WIN55,212-2 (P < 0.05). Lower panel: Effect 
of WIN55,212-2 on MOR-mediated analgesia. A priming dose of WIN55,212-2 (icv; 30 nmol) was administered to mice 24 h 
before testing the supraspinal analgesic response to morphine and DAMGO. Control mice received vehicle instead of the can-
nabinoid agonist. *Morphine displays significantly lower analgesic effect on mice that previously received WIN55,212-2 instead 
of vehicle (P < 0.05).Page 14 of 22
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Morphine reduces WIN55,212-12 analgesia in mice that do not express HINT1 proteinsFigure 7
Morphine reduces WIN55,212-12 analgesia in mice that do not express HINT1 proteins. Upper panel: Groups of 
eight mice each were injected icv with the opioids morphine, DAMGO, DADLE, and clonidine at the indicated doses, and the 
analgesic effect of WIN55,212-2 was assessed 24 h later. *Significantly different from the control group injected with the vehi-
cle instead of the priming dose of WIN55,212-2 (P < 0.05). Lower panel: The absence of HINT1 enables morphine to reduce the 
analgesic effects of WIN55,212-2. *Significantly different from the control animals (open bar) or from the group injected with 
the vehicle instead of the priming dose of morphine (P < 0.05).
Molecular Pain 2009, 5:11 http://www.molecularpain.com/content/5/1/11Figure 8 (see legend on next page)
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by the MOR. In agreement with this idea, disruption of
the HINT1-RGSZ module led acutely administered mor-
phine to promote a profound and long-lasting desensiti-
zation of brain MORs, and most relevant, impaired the
analgesic activity of CB1R agonists. Therefore, disruption
of Gz regulation brings about a bidirectional supraspinal
cross-tolerance between acute doses of morphine and can-
nabinoids, similar to that attained through chronic and
systemic administration of the respective MOR or CB1R
agonists [23,24].
Morphine poorly internalizes MORs and promotes strong
analgesic desensitization by stimulating permanent trans-
fer of a part of the receptor-regulated G proteins toward
RGS proteins belonging to the R7 and Rz subfamilies
[25,47,48,50]. In contrast, DAMGO produces a robust
internalization and recycling of MORs, a transient transfer
of G proteins toward the RGS proteins, and a low level of
analgesic tolerance [25]. Because icv-injected cannabi-
noids facilitated a reversible transfer of Gα subunits
toward RGSZ2 proteins and because the membrane levels
of CB1Rs were almost restored within 24 h of their initial
challenge, one should expect the resensitization of the
analgesic response to these substances, as with DAMGO.
However, our results reveal a long-term supraspinal anal-
gesic tolerance even after the CB1R reassociates with these
G proteins. This apparent divergence between DAMGO
and cannabinoids in the production of tolerance can be
explained in terms of the classes of G proteins activated by
these agonists after binding to their respective supraspinal
receptors. Thus, the analgesic effects of WIN55,212-2 are
mediated mostly by Gz proteins, whereas those of
DAMGO require Gi/o proteins and, to a lesser extent, Gz
[51,56,58,64]. In the absence of Gz activation, the can-
nabinoids behave as DAMGO, promoting low levels of
analgesic tolerance. Therefore, the desensitizing capacity
of Gz proteins on post-receptor events predominates over
the resensitization caused by reinsertion and G protein-
coupling of the internalized CB1Rs in the neural mem-
brane. Thus, it is the coincidence of WIN55,212-2 and
morphine at Gz proteins that accounts for their cross-
desensitization, whereas the poor regulation of this Gz by
DAMGO explains why WIN55,212-2 fails to impair
DAMGO-evoked analgesia.
Thus, an inefficient Gαz-GTP deactivation results in
desensitization of brain MORs and CB1Rs, suggesting a
post-receptor mechanism that appears to be regulated by
Gz proteins. However, at the spinal level CB1Rs primarily
regulate Gi/o proteins, and in the absence of Gz proteins,
tolerance is primarily achieved by reducing the density of
active surface receptors. Indeed, this is seen after repeated
systemic treatment with cannabinoids (see Introduction).
Conclusion
At the supraspinal level, CB1Rs are enriched in neurons,
whereas CB2Rs are expressed at very low levels. Brain
CB1Rs interact with the HINT1-RGSZ signaling module
and produce analgesia by regulating PTX-sensitive Gi/o
proteins and PTX-insensitive Gz proteins. A single icv
injection of WIN55,212-2, methanandamide, or ACEA
brings about a long-lasting tolerance that is not mediated
by the persistent loss of functional CB1Rs, but rather,
seems to involve the action of CB1R-activated Gαz subu-
nits on certain effector(s). Such effectors appear to be
common to CB1Rs and MORs, given their joint regulation
of Gz proteins and the fact that Gz deregulation results in
analgesic desensitization to cannabinoids and morphine.
Together with the findings of other groups, our results
suggest that both CB1Rs and MORs co-exist in certain
neurons within the brain, where they regulate Gz proteins
and similar effectors.
Methods
Drugs and production of antibodies
Arachidonyl-2¡-chloroethylamide (ACEA, Tocris #1319),
WIN55,212-2 mesylate (Tocris #1038), N-(piperidin-1-
yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-
1H-pyrazole-3-carboxamide (AM251, Tocris #1117), and
The CB1R carries the HINT1-RGSZ signaling moduleFigure 8 (see previous page)
The CB1R carries the HINT1-RGSZ signaling module. Upper panel: In solubilized PAG synaptosomal membranes, MOR 
and CB1R co-precipitated PKCI/HINT1 and RGSZ proteins. In contrast, the δ-opioid receptor (DOR) showed little association 
with these proteins. Middle panel: Zinc increases the association of PKCγ with PAG MOR and CB1R. PAG synaptosomes were 
solubilized and incubated with zinc (30 nM) for 4 h at 4°C. MORs and CB1Rs were immunoprecipitated, and co-precipitation 
of PKCγ was evaluated. Lower panel: WIN55,212-2 promotes the recruitment of PKCγ to the CB1 receptor. Mice were 
injected icv with a desensitizing dose of 20 nmol WIN55,212-2. The CB1 receptors were immunoprecipitated (IP) from PAG 
synaptosomes (P2) obtained at the indicated intervals following agonist administration. For each interval, the PAG from six to 
eight mice were pooled. Since this dose of WIN55,212-2 promotes internalization of PAG CB1Rs, equal loading was verified by 
examining the signals obtained by immunodetection of the heavy chain of the anti-CB1R IgGs. IgGs were detached from the 
immunoprecipitated CB1 receptors, processed in parallel gel/blots, and detected using the appropriate secondary antibody. 
Co-precipitation studies were performed under non-denaturing conditions, and the MOR- and CB1R-associated proteins were 
immunodetected with antibodies directed against PKCI/HINT1, PKCγ, RGSZ1, and RGSZ2.Page 17 of 22
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many) were dissolved in 1:1:18 (v/v/v) mixture of etha-
nol: cremophor EL (Sigma Chemical Co., Madrid):
physiologic saline. (R)-(+)-Methanandamide in Tocri-
solve™ 100 (Tocris #1782). [D-Ala2, N-Me-Phe4, Gly-ol5]-
enkephalin (DAMGO, Tocris #1171), clonidine hydro-
chloride (Tories #0690), [D-Ala2, D-Leu5]-encephalin ace-
tate salt (DADLE, Sigma #E7131), and morphine sulphate
(Merck, Darmstadt Germany) were prepared in saline.
Pertussis toxin (#516562) and Gö7874 (#365252) were
purchased from Calbiochem. The antibodies against
CB1R used in this study were produced in New Zealand
white rabbits (Sigma Genosys). The antiserum CB1-Nt
was raised against amino acid residues 53–66 of the recep-
tor (FRGSPFQEKMTAGD), and the antiserum CB-1EL was
raised against residues 177–188 of the murine CB1 recep-
tor (DFHVFHRKDSPN; accession code NP_031752).
Anti-CB1R IgGs were purified by affinity chromatography
using these synthetic peptides coupled to NHS-activated
Sepharose 4 Fast Flow (#17-0906-01, GE Healthcare Bio-
sciences) and labeled with biotin (Sigma #B1022) accord-
ing to the manufacturer's instructions.
Reduction of G protein and RGS protein expression
To interfere with the expression of the proteins of interest
we used synthetic end-capped phosphorothioate anti-
sense oligodeoxynucleotides (ODNs) which have previ-
ously been characterized. These were synthesized by
Sigma-Genosys Ltd. (Cambridge, UK). In the following
sequences, the nucleotides containing the phospho-
rothioate linkage are marked with an asterisk: 5'-
C*T*CGAATCAGTTCG*C*T-3' (16 nt), corresponding to
nucleotides 1044–1059 of the murine RGS9-2 mRNA
expressed in the CNS (AF125046) [48,52]; 5'-C*C*GAA-
GAGTCTCCTC*T*T-3' (17 nt), corresponding to nucle-
otides 281–297 of the murine RGSZ2 gene (AF191555)
[47]; 5'-T*G*TAATCTCACCCTTGCTCTCTGCT-
GGGCCA*G*T (33 nt), corresponding to nucleotides
1033–1065 of the murine Gαz subunit gene
(NM_010311) [49,50]; 5'-G*T*GGTCAGCCCA-
GAGCCTCCGGATGACGCCC*G*A (33 nt), correspond-
ing to nucleotides 477–502 of the murine Gαi2 subunit
gene (NM_008138) [49,50]; 5'-C*C*ATGCGGTTCT-
CATTGTC*T*G-3' (21 nt), corresponding to nucleotides
725–745 of the Gαq/Gα11 gene sequences (NM_008139/
NM_010301) [51]; 5'-T*T*GAGCCTTGGCAAT*C*T-3'
(17 nt), corresponding to nucleotides 11–27 of the
murine PKCI/HINT1 gene (NM_008248) [32]. These
sequences showed no homology to any other relevant
cloned proteins (GenBank database). Antisense ODN
controls consisted of mismatched sequences in which five
bases were switched without altering the remaining
sequence.
Animals, icv injection, and evaluation of antinociception
Male albino CD-1 mice (Charles River, Barcelona, Spain)
weighing 22–25 g were housed and used strictly in accord-
ance with the guidelines of the European Community for
the Care and Use of Laboratory Animals (Council Direc-
tive 86/609/EEC). Animals were kept at 22°C and were on
a 12-h light/dark cycle (lights on from 8 a.m. to 8 p.m.).
Food and water were provided ad libitum. Animals were
lightly anaesthetized with ether, and the different sub-
stances were injected into the lateral ventricle in a volume
of 4 μL as previously described [49]. The response of the
animals to nociceptive stimuli was assessed using the
warm water (52°C) tail-flick test. Baseline latencies
ranged from 1.5 to 2.2 seconds, and they were not signif-
icantly affected by the kinase inhibitor Gö7874, its sol-
vent, or the solvent used for the cannabinoid agonists:
Gö7874 in DMSO, 1.7 ± 0.1 seconds; DMSO alone, 1.8 ±
0.12 seconds (n = 10); saline, 1.8 ± 0.2 seconds; and eth-
anol/cremophor EL/physiologic saline (1:1:18), 1.9 ± 0.2
seconds (n = 10). A cut-off time of 10 seconds was used to
minimize the risk of tissue damage. Treatment with the
selected active and mismatched ODNs did not alter the
baseline latencies. Since the mismatched ODNs produced
no changes in cannabinoid/opioid activity compared to
saline-treated mice, the results obtained with these ODNs
are presented as controls. Antinociception is expressed as
a percentage of the maximum possible effect (MPE = 100
× [test latency-baseline latency]/[cut-off time-baseline
latency]). Groups of 10–15 mice received a dose of can-
nabinoid agonist and antinociception was assessed at dif-
ferent time intervals thereafter.
ODN solutions were prepared in the appropriate volume
of sterile water immediately prior to use. Animals received
either vehicle (control), the mismatched sequence ODN,
or the antisense oligo. These compounds were injected
into the right lateral ventricle. On days 1 and 2, 1 nmol
was injected; on days 3 and 4, 2 nmol was injected; and
on day 5, 3 nmol was injected. On day 6, the drugs were
injected icv and antinociceptive effects were evaluated
using the warm water tail-flick test. This schedule of
administration did not alter the normal behavior of the
mouse [69].
Production of acute tolerance
Animals were injected icv into the right lateral ventricle
with a dose of cannabinoid agonists sufficient to produce
70–80% of the maximum analgesic effect (priming dose).
The controls were given vehicle in the same manner. The
development of acute tolerance was monitored once the
priming dose was observed to have no effect on baseline
latencies. Thus, at 24 h an identical dose of agonist (test
dose) was administered icv to all the mice – both the treat-
ment and the control groups. Acute tolerance assays werePage 18 of 22
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after 10 min.
Astroglial cell cultures
Primary mixed glial cultures were prepared from 1-day-
old Wistar rat cortex following the procedure described
previously [70]. The cultures were maintained for 12 days
in DMEM + 10% FCS in a moist 5% CO2 atmosphere at
37°C. Enriched astrocytes cultures were obtained after
overnight shaking to minimize oligodendrocyte and
microglial contamination. For immunoprecipitation
studies, astrocytes grown in 75 cm2 flasks were pooled and
homogenized in 10 volumes of 25 mM Tris-HCl (pH 7.4),
1 mM EGTA, and 0.32 M sucrose supplemented with a
protease inhibitor cocktail (Sigma #P8340, Madrid,
Spain). The homogenate was centrifuged at 1000 g for 10
min (Sorvall RC5C, rotor SS-34, Newton, CT, USA). The
supernatant (S1) was removed and centrifuged at 20,000
g for 20 min to obtain the crude membrane pellet and the
cytosolic fraction.
For immunocytochemistry, the astrocytes were plated
onto poly-D-lysine-coated 10-mm glass coverslips at a
density of 20,000 cells/well. After replating, cultures were
maintained in DMEM + 10% FCS for 6 h and the serum
was reduced to 1% for no longer than 72 h. To label sur-
face CB1 receptors in living astrocytes, cells were incu-
bated with WIN55,212-2 for 1 h at 37°C., after which
CB1R antibodies (1:500) labeled with Alexa-488 were
added to the cultures. After 30 min the coverslips were
rinsed several times with 0.1 M phosphate-buffered saline
(PBS) and fixed with 4% paraformaldehyde in PBS for 7
min.
To label internalized CB1 receptors the cells were first
incubated with WIN55,212-2 for 1 h at 37°C. Afterwards,
the coverslips were rinsed several times with 0.1 M phos-
phate-buffered saline (PBS) and fixed with 4% parafor-
maldehyde in PBS for 7 min. This was followed by 45 min
incubation with 0.5% NGS, 1% BSA and 0.1% Triton
X100. The CB1R antibodies were incubated in this solu-
tion for 2 h at room temperature. Cells were observed
with a Leica DMIII 6000 CS confocal fluorescence micro-
scope equipped with a TCS SP5 scanning laser. Selectivity
of the immunosignal was confirmed by incubating the
antibodies with the antigenic peptide.
Preparation of membranes from neural cells and 
subcellular fractionation
This procedure has been described elsewhere [25,48].
Briefly, synaptosomal membranes were obtained from
groups of 6 to 10 mice that were sacrificed by decapitation
at various intervals after receiving icv injection of the com-
pounds. The PAGs were collected and homogenized in 10
volumes of 25 mM Tris-HCl (pH 7.4), and 0.32 M sucrose
supplemented with a phosphatase inhibitor mixture
(Sigma, P2850), H89 (Sigma, B1427) and a protease
inhibitor cocktail (Sigma, P8340). The homogenate was
centrifuged at 1000 g for 10 min to remove the nuclear
fraction. The supernatant (S1) was centrifuged twice at
20,000 g for 20 min to obtain the crude synaptosomal pel-
let (P2). The final pellet was diluted in Tris buffer supple-
mented with a mixture of protease inhibitors (0.2 mM
phenylmethylsulphonyl fluoride, 2 μg/mL leupeptin, and
0.5 μg/mL aprotinin) before aliquoting and freezing at
80°C. The supernatant (S2) was centrifuged at 105,000 g
for 1 h to obtain the crude microsomal pellet (P3) (Beck-
man XL-70 ultracentrifuge, rotor Type 70 Ti). The S3
supernatant was concentrated on an Amicon Ultra-4 cen-
trifugal filter device (nominal molecular weight limit
[NMWL] of 10,000; #UFC8 01024, Millipore Iberica S.A.,
Madrid, Spain), and it was then loaded on a 10–40% (w/
v) continuous sucrose gradient and centrifuged at
225,000 g for 18 h. Ten fractions (4 mL each) were col-
lected, the proteins concentrated, and the CB1Rs immu-
noprecipitated and analyzed by Western blotting.
Glycoprotein purification by wheat germ lectin affinity 
chromatography
Solubilization and wheat germ lectin (WGL) affinity chro-
matography were carried out at 4°C on neural mem-
branes resuspended in buffer A with 2% Triton X-100 (20
mM Tris-HCl, pH 7.5, 1 mM EGTA, supplemented with
protease inhibitor cocktail). The mixture was incubated at
4°C for 16 h with agitation and then centrifuged at
100,000 g for 1 h. The clear supernatant obtained was
applied at a rate of 1.5 mL/min to a WGL-Sepharose 4B
column (GE Healthcare Biosciences, #17-0444) previ-
ously equilibrated with 20 bed volumes of buffer A con-
taining 1% Triton X100, 1 mM CaCl2, and 1 mM MnCl2
(buffer B). The retained glycoproteins were then eluted
with 0.25 M N-acetyl-D-glucosamine in buffer B and were
collected in siliconized tubes in 1-mL fractions.
Co-immunoprecipitation of signaling proteins
Samples were sonicated (two cycles of 5 s each) in a vol-
ume of 400 μL containing 50 mM Tris-HCl (pH 7.7), 50
mM NaCl, 1% Nonidet P-40, and 50 μL of protease and
phosphatase inhibitor mixtures and H89. CB1Rs were
immunoprecipitated as described for MORs [25,32,48].
Pilot assays were carried out to optimize the amount of
IgGs and sample protein, as well as the period of incuba-
tion needed to precipitate the desired protein in a single
run. At the end of the procedure, proteins in the soluble
fraction were concentrated in centrifugal filter devices
(Amicon Microcon YM-10 #42407, Millipore) and solubi-
lized in 2× Laemmli buffer containing mercaptoethanol
by heating at 100°C for 3 min. After the samples cooled,
proteins were resolved by 10–16% SDS/PAGE.Page 19 of 22
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electrophoresis and immunoblotting
Western blots were probed with affinity-purified IgGs:
antibodies directed against peptide sequences in the
murine CB1R, i.e., CB1-Nt and CB1-1EL (diluted 1:1000);
anti-Gαi1, anti-Gαi2, anti-Gαz (1:2000), anti-Gαo and
anti-Gαq/11 (diluted 1:1000) [49,69]; anti-RGS20(Z1)
(1:1000) [54], anti-RGS17(Z2) [47], anti-MOR and anti-
DOR (1:3000) [45]; anti-PKCI/HINT1 (1:1000) [71]; and
anti-PKCγ (1:1000; BD Biosciences). The antibodies were
diluted in TBS + 0.05% Tween 20 (TTBS) and incubated
with the PVDF membranes for 24 h at 6°C. The primary
antibodies were detected using the corresponding second-
ary antibodies conjugated to horseradish peroxidase
(diluted 1:10,000 in TTBS). Antibody binding was visual-
ized with Immobilon Western Chemiluminescent HRP
substrate (Millipore #WBKLS0100), and the chemilumi-
nescence was recorded with a ChemiImager IS-5500
(Alpha Innotech, San Leandro, California) equipped with
a Peltier-cooled CCD camera that provided a real-time
readout of 30 frames per second (-35°C; high signal-to-
noise ratio; dynamic range of up to 3.4 optical density
units). Densitometry was performed using Quantity One
Software (BioRad) and expressed as the mean ± S.E. of the
integrated volume (average optical density of the pixels
within the object area/mm2). The assays were typically
performed two to three times on samples obtained from
independent groups of mice (n = 12), and the results were
always similar.
[35S]GTPγS Binding Assays
Agonist-stimulated [35S]GTPγS binding was assayed as
described previously [48]. Briefly, synaptosomal mem-
branes from mouse PAG (5 μg of protein) were incubated
for 120 min at 30°C in assay buffer containing 50 mM
Tris-HCl (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 1 mM
EDTA, 1 mM dithiothreitol, 10 μM GDP, 0.1% bovine
serum albumin, and 0.1 nM [35S]GTPγS, together with
varying concentrations of WIN55,212-2 (0.1–10 μM).
Nonspecific [35S]GTPγS binding was assessed by carrying
out the above reactions in the presence of 20 μM unla-
beled GTPγS. The incubation was terminated by rapid fil-
tration under vacuum through Whatman GF/B filters,
followed by three washes with 3 ml of ice-cold 50 mM
Tris-HCl (pH 7.2). Bound radioactivity was determined
by liquid scintillation spectrophotometry using a Beck-
man LS-6500 scintillation counter.
Statistics
All statistical analyses were performed using ANOVA with
a Student-Newman-Keuls posthoc test (SigmaStat, SPSS
Science Software, Erkrath, Germany), and significance was
defined as P < 0.05.
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